Prolonged therapy in eosinophilic esophagitis is safe and reduces the risk of long-term histologic relapse.

Dose reduction from induction to maintenance does not significantly compromise treatment efficacy.

Corticosteroids and biologics provide comparable rates of histologic remission, each effective in over three-quarters of patients.

Proton pump inhibitors show favorable histologic and clinical outcomes in observational studies, though with some variability.

Maintenance therapy should generally be continued to sustain remission, but further studies are needed to define optimal dosing and identify patients who may safely discontinue therapy.

Source: Clinical Gastroenterology and Hepatology